Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Hongjiang Yuan"'
Autor:
Fuding Chen, Gang Du, Meishu Shih, Hongjiang Yuan, Peng Bao, Sheng Shi, Yong Cang, Zhen Zhang
Publikováno v:
PLoS ONE, Vol 14, Iss 12, p e0227202 (2019)
Adipocytes attached to the extracellular matrix (ECM) mainly consist of collagen in adipose tissues, while the degradation of ECM by collagenase induces the apoptosis of adipocytes, leading to a decrease in local subcutaneous adipose. To achieve this
Externí odkaz:
https://doaj.org/article/d4fb2e3fe46a474988a53d3bab776683
Autor:
Fang Yuan, Dana E Tabor, Richard K Nelson, Hongjiang Yuan, Yijia Zhang, Jenny Nuxoll, Kimberly K Bynoté, Subodh M Lele, Dong Wang, Karen A Gould
Publikováno v:
PLoS ONE, Vol 8, Iss 11, p e81483 (2013)
We evaluated the ability of a macromolecular prodrug of dexamethasone (P-Dex) to treat lupus nephritis in (NZB × NZW)F1 mice. We also explored the mechanism underlying the anti-inflammatory effects of this prodrug. P-Dex eliminated albuminuria in mo
Externí odkaz:
https://doaj.org/article/5ed0abc4a4504c2fbd2ff04d75d0ac4e
Autor:
Laura Weber, Gang Zhao, Xin Wei, Xiaobei Wang, Dong Wang, Rongguo Ren, Huiling Pang, Hongjiang Yuan, Hanjun Wang, Junxiao Yang
The addictive potential of clinically used opioids as a result of their direct action on the dopaminergic reward system in the brain has limited their application. In an attempt to reduce negative side effects as well as to improve the overall effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfe16cb2b5a2ca8161da4b4c5f07f62b
https://europepmc.org/articles/PMC6413733/
https://europepmc.org/articles/PMC6413733/
Publikováno v:
Clinical Immunology. 160:71-81
A macromolecular prodrug (P-Dex) of dexamethasone (Dex) was developed to improve the treatment of inflammatory bowel disease (IBD). Colonic inflammation was induced by feeding mice with dextran sulfate sodium. Mice were treated with daily i.p. inject
Autor:
Aaron Daluiski, Anand Dusad, Hongjiang Yuan, Edward V. Fehringer, P. Edward Purdue, Yijia Zhang, Yen Hsun Chen, Steven R. Goldring, Ke Ren, Zhenshan Jia, Dong Wang, Fei Li
Publikováno v:
Journal of Controlled Release. 200:23-34
Simvastatin (SIM), a widely used anti-lipidaemic drug, has been identified as a bone anabolic agent. Its poor water solubility and the lack of distribution to the skeleton, however, have limited its application in the treatment of bone metabolic dise
Autor:
P. Edward Purdue, Ke Ren, Kevin L. Garvin, Edward V. Fehringer, Anand Dusad, Steven R. Goldring, Fang Yuan, Dong Wang, Hongjiang Yuan
Publikováno v:
Journal of Controlled Release. 175:1-9
Aseptic implant loosening related to implant wear particle-induced inflammation is the most common cause of failure after joint replacement. Modulation of the inflammatory reaction to the wear products represents a rational approach for preventing as
Autor:
Dana E. Tabor, Kimberly K. Bynoté, Jenny S. Nuxoll, Subodh M. Lele, Fang Yuan, Dong Wang, Richard K. Nelson, Yijia Zhang, Hongjiang Yuan, Karen A. Gould
Publikováno v:
PLoS ONE
PLoS ONE, Vol 8, Iss 11, p e81483 (2013)
PLoS ONE, Vol 8, Iss 11, p e81483 (2013)
We evaluated the ability of a macromolecular prodrug of dexamethasone (P-Dex) to treat lupus nephritis in (NZB × NZW)F1 mice. We also explored the mechanism underlying the anti-inflammatory effects of this prodrug. P-Dex eliminated albuminuria in mo
Publikováno v:
Bone. 43:S75
Autor:
Hongjiang Yuan
Publikováno v:
Health Policy and Planning. 5:192-192